Civica aims to launch low-cost insulin in US by 2024
Civica, launched in 2018 to make generic drugs, said it would produce three copycat versions of insulin
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lantus
Viatris wins US court decisions on Sanofi appeals for Lantus device patents
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Biocon Biologics and Viatris launch interchangeable Semglee
Branded and unbranded versions of the first-ever interchangeable biosimilar in the US provide more affordable options for the…
Approval of first interchangeable biosimilar insulin to increase competition with payer contracts:…
While patients will be increasingly prescribed Viatris/Biocon’s Semglee over Sanofi’s Lantus due to its competitive pricing,…